๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Primary Peritoneal Carcinoma
Clinical trial register · China

Primary Peritoneal Carcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 8 Guangzhou 4 Hangzhou 4 Shenzhen 3 Beijing 3
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai8 Guangzhou4 Hangzhou4 Shenzhen3 Beijing3
All 13 locations
Target enrolment
to

Primary Peritoneal Carcinoma trials in China

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
NCT07674615Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 1
19
Shanghai
2026-07-01
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRฮฑ, MUC16) pt2
NCT07617753Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRฮฑ, MUC16)
NCT07480954Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-02-04
Not yet open
Surgery for Relapsed Ovarian Cancer in Precision
NCT06602063Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 1/2
33
Shanghai, Wuhan
2025-07
Recruiting
Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
NCT07023484Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
The University of Hong Kong
Phase 2
126
Guangzhou, Shenzhen
2025-05-22
Recruiting
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
NCT06420973Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Peking University Cancer Hospital & Institute
Phase 2
54
Beijing
2024-05-16
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Genmab
Phase 1/2
884
Beijing, Chongqing, Changsha, Nanchang, Changchun, Chengdu, Shanghai, Hangzhou
2022-12-07
Recruiting
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
NCT05200260Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 2
220
Foshan, Guangzhou, Hangzhou, Hefei, Shanghai
2022-07-13
Recruiting
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
NCT05236686Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Not applicable
94
Shanghai
2022-02-15
Recruiting
A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
NCT04834544Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Peking University Third Hospital
Phase 2
75
Beijing
2021-04-19
Not yet open
Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
NCT04515602Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 3
410
Shanghai
2021-01
Recruiting
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
NCT03983226Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 2
167
Shanghai, Guangzhou, Hangzhou
2019-10-18
Active, closed
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
NCT02859038Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 3
489
Guangzhou, Shanghai, Hangzhou, Changsha
2016-08
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/primary-peritoneal-carcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies listing the condition Primary Peritoneal Carcinoma.

How many Primary Peritoneal Carcinoma trials are recruiting in China?

9 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Primary Peritoneal Carcinoma), 13 studies
PhaseStudiesRecruitingShare
Phase 25538.5%
Phase 1/24330.8%
Phase 32015.4%
Not applicable117.7%
Phase 1107.7%

Most active sponsors

Lead sponsors with the most studies (Primary Peritoneal Carcinoma)
Lead sponsorStudiesRecruiting
Shanghai Gynecologic Oncology Group73
Beijing Biotech22
Genmab11
Peking University Cancer Hospital & Institute11
Peking University Third Hospital11
The University of Hong Kong11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.